All In Biotech

Drug Trial Radar · NCT07271147

Effects of taVNS Combined With Dexmedetomidine on POVN

The Effect of Dexmedetomidine Combined With Percutaneous Auricular Vagus Nerve Stimulation on Postoperative Nausea and Vomiting in Female Laparoscopic Patients: A Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 176 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

176

Planned (sponsor's estimate)

Start

Dec 7, 2025

Primary completion

Dec 1, 2026

Study completion Dec 1, 2026

Sponsor

Lead sponsor
Affiliated Hospital of Nantong UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To explore the effects and possible mechanisms of dexmedetomidine combined with taVNS on the incidence of postoperative nausea and vomiting in female patients undergoing laparoscopic surgery

Conditions

  • Postoperative Nausea and Vomiting

Interventions

  • Transcutaneous Auricular Vagus Nerve StimulatorDevice

    Intervention Timing of Transcutaneous Auricular Vagus Nerve Stimulator: The intervention will begin 30 minutes before anesthesia induction and continue until the end of the surgery, terminating after the removal of the endotracheal tube in the PACU. The stimulation parameters are set as follows: frequency 25 Hz, pulse width 200 μs, 30 seconds on / 30 seconds off, with the current intensity set to the maximum amplitude the patient can tolerate (just below the pain threshold).

  • DexmedetomidineDrug

    Dexmedetomidine was administered intravenously by infusion pump (0.5 μg/kg over 10 minutes, followed by continuous infusion at 0.4 μg/kg/h) in combination with taVNS (initiated 30 minutes before anesthesia induction and terminated after tracheal tube removal in the PACU upon the conclusion of the surgery).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Postoperative PONVTime frame: The first 24 hours postoperatively

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliated hospital of Nantong University

    Nantong, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.